Novo Nordisk A/S (NYSE:NVO)

51.23
Delayed Data
As of Oct 11
 -0.42 / -0.81%
Today’s Change
41.23
Today|||52-Week Range
53.55
+11.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$92.6B

Company Description

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé
Bagsværd Capital Region 2880
P:(454) 444-8888
Investor Relations:
(453) 075-9085

Employees

Shareholders

Other institutional7.42%
Mutual fund holders1.97%
Individual stakeholders--

Top Executives

Lars Fruergaard JørgensenPresident & Chief Executive Officer
Maziar Mike DoustdarExecutive Vice President-International Operations
Karsten Munk KnudsenChief Financial Officer & Executive Vice President
Mads Krogsgaard ThomsenChief Science Officer & Executive Vice President
Alan C. MosesSenior Vice President & Chief Medical Officer